תחזית צמיחת רווח נקי למניה לשנה הבאה Cellectar (CLRB)

Cellectar Biosciences (CLRB) is scaling its PDC platform to expand within the radiopharmaceutical segment, and on GURU.Markets, this promising eps n+1 growth metric demonstrates that the current value is 17.90. The business relies on technology for the targeted transport of isotopes into tumors. High demand in the underserved niche of rare hematological diseases provides the company with significant market prospects.

This metric is calculated as the percentage ratio of expected net earnings per share in the next period to the current value. It measures market expectations regarding the business scaling rates and the financial stability of the issuer. The high authority of Cellectar Biosciences (CLRB) in oncology and the success of Iopofosine make the earnings per share growth forecast trend on GURU.Markets a key indicator of brand capitalization.